Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT02202772
What this trial is testing

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Who this might be right for
Urothelial Carcinoma of the Urinary Bladder
Guarionex J. Decastro 51
Testing effectiveness (Phase 2)Ended earlyNCT01216657
What this trial is testing

Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma

Who this might be right for
Chemo-refractory Melanoma
Krankenhaus Nordwest 7
Large-scale testing (Phase 3)Active Not RecruitingNCT00114101
What this trial is testing

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Who this might be right for
DS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple Myeloma+2 more
National Cancer Institute (NCI) 460
Early research (Phase 1)Study completedNCT00002912
What this trial is testing

Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia

Who this might be right for
Leukemia
National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)Study completedNCT00783367
What this trial is testing

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

Who this might be right for
Follicular LymphomaMarginal Zone B-Cell LymphomaMALT Lymphoma+4 more
Abramson Cancer Center at Penn Medicine 50
Early research (Phase 1)Ended earlyNCT05038800
What this trial is testing

Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)

Who this might be right for
Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic Leukemia
Merck Sharp & Dohme LLC 13
Testing effectiveness (Phase 2)Study completedNCT02395822
What this trial is testing

MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Who this might be right for
Acute Myelogenous Leukemia
Masonic Cancer Center, University of Minnesota 17
Not applicableUnknownNCT05875402
What this trial is testing

XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation

Who this might be right for
Colon Cancer
The Affiliated Hospital of Qingdao University 9
Not applicableEnded earlyNCT03540953
What this trial is testing

Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis

Who this might be right for
Esophageal StenosisDeglutition DisordersHead and Neck Neoplasms+1 more
Fauze Maluf Filho 12
Early research (Phase 1)Study completedNCT02852837
What this trial is testing

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 50
Testing effectiveness (Phase 2)UnknownNCT02638428
What this trial is testing

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Who this might be right for
Relapsed Pediatric Solid TumorRefractory Pediatric Solid TumorRelapsed Pediatric AML+1 more
Samsung Medical Center 90
Testing effectiveness (Phase 2)Looking for participantsNCT06450041
What this trial is testing

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Who this might be right for
Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium 62
Early research (Phase 1)Study completedNCT00306202
What this trial is testing

Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia

Who this might be right for
Leukemia
Bristol-Myers Squibb 63
Testing effectiveness (Phase 2)Looking for participantsNCT06193902
What this trial is testing

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

Who this might be right for
Tumor, Solid
Leucid Bio 17
Testing effectiveness (Phase 2)Study completedNCT01462253
What this trial is testing

Clofarabine-cyclophosphamide as Salvage Therapy for Refractory and Relapsed Acute Lymphoblastic Leukemia (ALL) Adults

Who this might be right for
Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 35
Testing effectiveness (Phase 2)Study completedNCT03415477
What this trial is testing

Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts

Who this might be right for
Bone Cyst AneurysmalPathological FractureRecurrent Disease+1 more
Peking University People's Hospital 6
Very early researchUnknownNCT05886075
What this trial is testing

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

Who this might be right for
Lung CancerBronchial CancerNon Small Cell Lung Cancer+9 more
Shanghai Yunying Medical Technology 24
Testing effectiveness (Phase 2)Study completedNCT01720875
What this trial is testing

Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

Who this might be right for
Multiple Myeloma
University of Leeds 16
Not applicableNo Longer AvailableNCT02368301
What this trial is testing

Expanded Access Treatment Protocol CA204-143

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Study completedNCT01450319
What this trial is testing

Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype

Who this might be right for
Colorectal Neoplasms
Merck KGaA, Darmstadt, Germany 73
Next Page